GE HealthCare Technologies Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $GEHC in the last 30 days.
See all $GEHC insider activity →BTIG maintained a Buy rating and $79 price target for GE HealthCare (GEHC) after positive feedback on its new photon-counting CT system. GEHC stock is down 22% YTD but is considered undervalued. The company reported Q2 revenue of $5.295B, beating estimates, and raised its price target to $85. GEHC's backlog reached $23.9B, indicating strong demand.
GE HealthCare (GEHC) is reportedly in talks to acquire Sofie Biosciences for $1B. Sofie holds U.S. rights to F-18 FAPI-74, a radiotracer for PET scans. GEHC already licensed global rights to Gallium-68 FAPI-46 and non-U.S. rights to F-18 FAPI-74. Sofie operates seven radiopharmacies producing F-18 FAPI-74. The deal's value depends on additional rights, manufacturing earnings, and operational benefits.
GE HealthCare (GEHC) granted its CFO, William K. Grogan, 31,877 stock options with a $64.25 exercise price, expiring in 2036, and 75,096 restricted stock units (RSUs) on September 14, 2026. The RSUs vest in 2027-2029. No Rule 10b5-1 trading plan was reported.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning GEHC (GE HealthCare Technologies Inc.). Coverage has skewed bullish: 7 bullish, 2 neutral, and 0 bearish.
Recent GEHC coverage spans financial news, mergers & acquisitions and earnings.
Positive earnings beat and regulatory approval may lift the stock toward the new $79 target.
Potential acquisition could expand GEHC's radiotracer portfolio and manufacturing capabilities.
Small insider compensation award with no immediate price impact.
The product could drive incremental SaaS revenue and expand GEHC's footprint in hospital operations.
The acquisition would expand GEHC's radiopharmaceutical portfolio, likely boosting its diagnostics revenue.
AlphAI scores every news story that mentions GEHC with an AI model for sentiment and relevance, and aggregates insider trades from GE HealthCare Technologies Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BTIG maintained a Buy rating and $79 price target for GE HealthCare (GEHC) after positive feedback on its new photon-counting CT system. GEHC stock is down 22% YTD but is considered undervalued. The company reported Q2 revenue of $5.295B, beating estimates, and raised its price target to $85. GEHC's backlog reached $23.9B, indicating strong demand.
2 min readGE HealthCare (GEHC) is reportedly in talks to acquire Sofie Biosciences for $1B. Sofie holds U.S. rights to F-18 FAPI-74, a radiotracer for PET scans. GEHC already licensed global rights to Gallium-68 FAPI-46 and non-U.S. rights to F-18 FAPI-74. Sofie operates seven radiopharmacies producing F-18 FAPI-74. The deal's value depends on additional rights, manufacturing earnings, and operational benefits.
3 min readGE HealthCare (GEHC) granted its CFO, William K. Grogan, 31,877 stock options with a $64.25 exercise price, expiring in 2036, and 75,096 restricted stock units (RSUs) on September 14, 2026. The RSUs vest in 2027-2029. No Rule 10b5-1 trading plan was reported.
1 min readGE HealthCare launched CareIntellect for Operations, an AI-driven SaaS platform forecasting hospital capacity up to 72 hours ahead. Duke Health and The Queen’s Health Systems will implement it. The platform, hosted on AWS, uses machine learning to predict inpatient capacity and discharge timing, offering prescriptive workflow recommendations. GE HealthCare reports existing Command Center software has saved customers up to $20 million annually.
2 min readGE HealthCare is reportedly in talks to acquire Sofie Biosciences for $1 billion, according to the Financial Times. Sofie specializes in radiopharmaceuticals used in cancer scans. A deal could be announced next week. GE HealthCare has not commented. Sofie's technology could enhance GE HealthCare's diagnostics division.
2 min readZoetis appointed Jay Saccaro as Executive Vice President, CFO, and COO, combining finance and operations. Saccaro previously served as CFO at GE HealthCare and Baxter. GE HealthCare named William Grogan as CFO, effective September 14, succeeding Saccaro.
2 min readGE HealthCare Technologies (GEHC) reported that CEO Jeannette Bankes had 1,064 shares withheld on September 1, 2026, to cover taxes on vested restricted stock units. The shares were valued at $71.23 each, totaling $76K. Bankes holds 37,293 shares directly after the transaction.
1 min readGE HealthCare (GEHC) CTO Taha Kass-Hout had 2,940 shares withheld on September 1, 2026 to cover tax obligations from vested restricted stock units. The shares were withheld at $71.23 each, totaling $209,000 in value. No 10b5-1 trading plan was involved.
1 min readGE HealthCare (GEHC) disclosed that CEO Philip Rackliffe had 856 shares withheld for tax obligations related to vested restricted stock units. The shares were withheld at $71.23 per share on September 1, 2026, and were not open-market sales. Rackliffe holds 42,331 shares post-transaction.
1 min readGE HealthCare Technologies (GEHC) received CE Mark approval for its Photonova Spectra photon counting CT system, allowing commercialization in Europe. The system aims to provide higher resolution CT imaging, potentially influencing future equipment investments by healthcare providers. GE HealthCare, valued at approximately $31.8 billion, focuses on integrating advanced imaging with digital tools.
3 min read
